Piper Sandler Boosts Oscar Health, Cites Resilience in Face of ACA Credit Shifts
Table of Contents
Oscar Health is poised for growth despite potential headwinds in the Affordable Care Act (ACA) marketplace, according to a new report from Piper Sandler. The investment firm upgraded its rating of the health tech provider to overweight from neutral, alongside a significant price target increase to $25 – a 49% jump from its previous $13 estimate.
The bullish outlook stems from research into Oscar Health’s performance in Miami-Dade County, its largest market, offering insights into the company’s potential trajectory as key federal subsidies expire. Shares of Oscar Health (OSCR) have already risen 24% year-to-date.
A major factor influencing the forecast is the anticipated expiration of enhanced advance premium tax credits (E-APTCs) at the end of calendar year 2025. According to the analysis, Oscar Health anticipates both its market share and profit margins will expand year-over-year even as these credits lapse.
However, the firm acknowledges the potential for significant enrollment declines. One analyst wrote that if the E-APTCs are not extended, the Individual ACA Marketplace could see enrollment fall between 20% and 30% in 2026. This translates to a potential loss of approximately 6.1 million lives, shrinking the market from roughly 24.3 million enrollees in 2025 to 18.2 million in 2026. This projected decline reflects both the end of the credits and increased federal scrutiny of program integrity.
Proactive Product Design for 2026
Despite the challenging outlook, the report highlights Oscar Health’s proactive approach to preparing for this shift. The company has not only priced its products to withstand the changes but has also specifically designed its 2026 offerings for an adverse operating environment.
Oscar Health has launched and expanded condition-specific products, such as HelloMenu, a program geared towards women experiencing menopause. These targeted offerings are designed to reduce underwriting risk, boost member engagement, and improve clinical outcomes. “Oscar’s 2026 product portfolio is structured for retention and priced for margin recapture,” one analyst noted. “Most Oscar members will be able to buy-down to a similar plan at a different metal level in 2026,” preserving continuity of care and mitigating the impact of increased premiums.
Incentivizing Sales and Strategic Enrollment
Piper Sandler also praised Oscar Health’s new bonus program for brokers and agents. The program incentivizes high volumes of new sales booked in November for coverage starting January 1. “November tends to be the slowest month of [open enrollment period], where brokers/ agents have the most capacity for consultation,” a source explained. “Oscar’s new compensation paradigm will pull sales into November and ensure deliberate/ appropriate plan selection for 2026.”
This strategic move aims to capitalize on a traditionally slow period and ensure members select plans best suited to their needs as the subsidy landscape changes.
The analysis suggests Oscar Health is well-positioned to navigate the evolving ACA marketplace, demonstrating both resilience and a forward-thinking approach to product development and sales strategy.
